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Abstract
Background
Cell free deoxyribonucleic acid (cfDNA) has been proposed as a biomarker of secondary
complications following trauma. Raised thrombomodulin and syndecan-1 levels have been
used to indicate endotheliopathy, and are associated with inflammation, coagulopathy, and
mortality. The current study aimed to analyse the association between cfDNA and biomark-
ers of endotheliopathy in a cohort of trauma patients, and whether raised levels of cfDNA
were associated with poorer clinical outcomes.
Methods
Serum thrombomodulin and syndecan-1 were used as biomarkers of endotheliopathy and
compared to plasma cfDNA in trauma patients from two prospective longitudinal observa-
tional studies. Cohort A (n = 105) had a predicted injury severity score (ISS) >8, and had
blood sampled within 1h of injury and at 4–12h. Cohort B (n = 17) had evidence of haemor-
rhagic shock, and had blood sampled at a median time of 3.5h after injury. Relationships
between biomarkers were tested using multivariable linear regression models that included
the covariates of gender, age, ISS, Glasgow Coma Scale, lactate, systolic blood pressure,
and heart rate. A model was fitted to investigate whether changes in cfDNA were associated
with similar changes in endothelial biomarkers.
Results
The mean age was 41 (SD 19), and the median ISS was 25 (IQR 12–34). There was a sig-
nificant association between cfDNA levels and both syndecan-1 and thrombomodulin levels
(both p<0.001). This was independent of all covariates except for ISS, which significantly
correlated with cfDNA levels. 50 ng/ml change in syndecan-1 and 1 ng/ml change in
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thrombomodulin corresponded to 15% and 20% increases in cfDNA levels respectively
(both p<0.001). Patients who died had significantly higher prehospital and in-hospital cfDNA
levels (both p<0.05).
Conclusions
Raised cfDNA levels are associated with markers of endotheliopathy following trauma, and
are associated with mortality. This relationship is present within the first hour of injury, and a
change in one biomarker level is reflected by similar changes in the others. These findings
are in keeping with the hypothesis that circulating DNA and endothelial injury share a com-
mon pathway following trauma.
Introduction
Cell-free deoxyribonucleic acid (cfDNA) is defined as extracellular DNA present within the
circulation. It consists of a combination of nuclear and mitochondrial DNA (mtDNA) that
enters the circulation following cell necrosis [1], tissue injury, and the generation of extracellu-
lar traps by activated immune cells such as neutrophils [2] and monocytes [3]. cfDNA may be
elevated due to bacterial infection, and mtDNA shares structural similarities with pathogen–
associated molecular patterns (such as those derived from bacteria). These fragments may
therefore activate the innate immune response following aseptic injury, and contribute in part
to the systemic inflammatory response observed following trauma [4–7]. The presence of
cfDNA may also give rise to coagulopathy by coagulation factor activation, platelet aggrega-
tion, and inhibition of fibrinolysis [8, 9], whilst neutrophil extracellular traps (NETs) may
cause further tissue injury and endothelial barrier dysfunction [10]. cfDNA has received inter-
est as a biomarker following injury in relation to mortality [1, 11], organ failure [12], inflam-
mation [2], and sepsis [13].
Syndecan-1 and thrombomodulin have been reported as biomarkers of endothelial cell and
glycocalyx injury in multiple recent studies of trauma [14–16]. The former is a transmembrane
heparan sulfate proteoglycan that forms part of the endothelial glycocalyx, and the latter is an
integral membrane protein present on the surface of endothelial cells throughout the circula-
tion. Raised levels of these biomarkers are associated with coagulopathy [14, 15, 17, 18],
inflammation [15], poor microcirculatory flow[19], organ failure[20], and mortality [15–17].
Experimental models have demonstrated that mtDNA directly increases endothelial perme-
ability through both neutrophil-independent and dependent pathways [21], and that it may
induce a pro-thrombotic phenotype within the endothelium [22]. These findings suggest that
there is likely to be a relationship between cfDNA and endotheliopathy, and that each may be
mutually detrimental to the other. Indeed there is some preclinical evidence that endothelial
cell damage by cfDNA is dose-dependent [23]. Other investigators have reported an associa-
tion between endotheliopathy and elevation of cfDNA levels on admission to hospital follow-
ing injury [15, 24, 25], but to our knowledge this has not been investigated within the pre-
hospital period following trauma.
The current study aimed to investigate the levels of cfDNA and biomarkers of endotheliopa-
thy following injury in a prospective cohort of trauma patients, and whether these biomarkers
were associated with each other over time, from the pre-hospital period to hospital admission.
We also aimed to investigate whether there was an association between levels of cfDNA and
clinical outcomes, and with markers of coagulopathy.
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We hypothesised that higher levels of biomarkers of endotheliopathy would be associated
with higher levels of cfDNA, that this would be true even within the first hour of injury, and
that there would be an association with markers of coagulopathy. We further hypothesised
that an increase or decrease over time in each biomarker would be associated with the same
directional changes in the others, and that raised cfDNA levels would be associated with
poorer clinical outcomes. We hypothesised that patients who received a blood transfusion or
had surgery would have increased levels of cfDNA when compared to those who did not.
Methods
Study design and setting
The current study combines data from two prospective longitudinal observational studies of
trauma patients conducted at a single Major Trauma Centre site in the UK (University Hospi-
tals Birmingham NHS Foundation Trust, Birmingham); these included patients from the
Brain Biomarkers after Trauma (BBATS)[20] (REC reference: 13/WA/0399) and MICRO-
SHOCK[19, 26] (REC reference: 14/YH/0078) studies. The former study (Cohort A) included
patients with a predicted ISS >8, regardless of mechanism of injury or blood product require-
ment between May 2014 and February 2017. The latter (Cohort B) included patients with trau-
matic haemorrhagic shock requiring blood product transfusion, with a lactate > 2 mmol/l,
and a requirement for intensive care between July 2015 and January 2017.
Capacity and consent
As all patients lacked capacity to consent for study participation at the time of study enrol-
ment, subjects were enrolled under the guidance of the Mental Health Act 2005 and the Decla-
ration of Helsinki. Both the MICROSHOCK and BBATS studies were approved to gain
consent to participate from a physician in charge of the care of the patient, but unrelated to the
studies (Professional Consultee). Where appropriate, agreement for study participation was
also obtained from a close friend or family of the patient (Personal Consultee). Ultimately, if
the patient regained capacity, they were asked for consent to remain within the study, and for
their previous data to be retained. If they did not regain capacity, then previous permissions
from their Professional or Personal Consultee remained extant.
Study time points
Patients in Cohort A all had blood sampled within the first 1 hour of injury by pre-hospital
personnel (median time 44 (range 14–60) minutes). They then had a further sample taken
between 4–12 hours following injury. Patients in Cohort B had blood sampled as soon as possi-
ble following admission to hospital, with a median time to sample of 3.5 (range 1–16) hours.
For the purposes of the current study, two time points were investigated, as illustrated in Fig 1:
(i) Pre-hospital (< 1 hour) (Cohort A only); and (ii) the first day of admission to hospital (1–
16h) (Cohorts A and B).
Blood sampling and preparation
All patients underwent venepuncture to obtain blood samples for research purposes using BD
Vacutainers1 (Becton Dickinson, Oxford, UK). For serum and plasma preparation, blood was
collected into vacutainers containing z-serum clotting activator or a 1/10 volume of 3.2% triso-
dium citrate respectively. After 30 minutes at room temperature, serum samples were centri-
fuged for 10 minutes at 1,620 x g. Plasma samples were centrifuged twice in order to minimise
platelet contamination. First, samples were centrifuged for 20 minutes at 2,000 x g, then the
Endotheliopathy and cell-free DNA in trauma
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top two thirds of fluid were spun again for 2 minutes at 13,000 x g. All centrifugation was per-
formed at 4˚C. Aliquots of serum and plasma were stored at -80˚C, until they were analysed en
masse.
Measurement of endothelial biomarkers
The concentrations of thrombomodulin (CD 141) and syndecan-1 (CD 138) in serum samples
were quantified using commercially available enzyme-linked immunosorbent assay kits
(Abcam, Cambridge, MA) in precise accordance with manufacturer instructions. Each 96 well
plate included a standard curve to interpolate the concentrations of biomarkers, as well as
blank and control wells to validate the results.
Fig 1. Flow diagram of study patients and samples available for analysis.
https://doi.org/10.1371/journal.pone.0189870.g001
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Measurement of cell-free DNA
In order to measure the cfDNA concentration in plasma samples, a fluorometric assay using
SYTOX1 Green Dye (Life Technologies, Cheshire, UK) was used as described previously
[13]. For each plate, a standard curve was generated using samples of λ-DNA (Fisher Scientific,
UK) ranging from 0–1000 ng/ml. To ensure that the assay was reliable between samples and
assays, the inter-assay and intra-assay coefficients of variation were calculated; these were 5.3%
and 5.1% respectively. 140 μl of SYTOX1 Green Dye (Final concentration 1 μM) was added
to 10 μl of plasma, and incubated for 10 minutes at room temperature in the dark. All samples
were run in duplicate. Fluorescence was then measured using a BioTek Synergy 2 fluorometric
plate reader (NorthStar Scientific Ltd, UK). Calibration was set at 485 nm and 528 nm for exci-
tation and emission respectively. The average values of the duplicate wells were then used to
derive cfDNA concentrations by interpolating from the standard curve.
Data collection
Demographic and clinical data were obtained prospectively for all patients using a combination
of electronic medical records and bedside medical notes. Data included age, sex, comorbidities,
body mass index (BMI), smoking and alcohol status, injury severity score (ISS), mechanism of
injury, lactate, systolic blood pressure, heart rate (HR), international normalised ratio (INR),
partial thromboplastin time (PTT) ratio, and Glasgow Coma Scale (GCS). A Charlson Comor-
bidity Index was calculated for all patients based on the presence of comorbidities. Since it is
possible that blood transfusion might also increase levels of cfDNA in transfused patients due to
the cfDNA within donated blood products[27], patients who had been transfused between time
points were recorded. Similarly, since surgery may also increase levels of cfDNA due to direct
injury, patients who had surgery between time points were noted.
Outcomes
Outcomes included 30-day mortality, thromboembolic events, as well as hospital-free and
ICU-free days (calculated as 30 minus the number of days in hospital and ICU respectively).
Data analysis
Normality of data was tested using the Shapiro-Wilk test. Continuous data are presented as
mean and standard deviation (SD) for normal data, and median and interquartile range (IQR)
for non-normal data. Categorical data are presented as N (%). Continuous data are compared
using t-tests for normal data and Mann-Whitney U tests for non-normal data as appropriate.
Categorical data are compared using Fisher’s exact test. Correlations have been tested using
Spearman’s rank correlation co-efficient. The relationships between cfDNA and endothelial
biomarkers were examined at both time points using multivariable linear regression models
that included the covariates of gender, age, ISS, GCS, lactate, SBP, and HR. In order to deter-
mine whether levels of endothelial biomarkers followed the same directional change as cfDNA
between time points, a model was fitted to examine the value of cfDNA at the second time
point as a function of the change in Syndecan-1 and thrombomodulin values, modified by
other covariates (gender, age, ISS, GCS, lactate, SBP, and HR) and the value of cfDNA at the
first time point. A p-value of<0.05 was considered significant. Analyses were performed using
R version 3.2.2 (http://www.r-project.org) and GraphPad Prism version 7.0 (GraphPad Soft-
ware, California, USA).
Endotheliopathy and cell-free DNA in trauma
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Results
Patient characteristics
There were 122 patients included (105 from Cohort A and 17 from Cohort B), with a mean
age of 41 (SD 19) and median ISS of 25 (IQR 12–34). A flow diagram of patients and available
cfDNA at each time point is illustrated in Fig 1. Five of the patients in Cohort A did not have
sufficient plasma and serum samples at the prehospital time point for comparison between
biomarkers, making the denominator for the prehospital time point N = 100. There were a fur-
ther 12 patients in Cohort A that had insufficient samples for the second time point, making
the denominator for the in-hospital time point N = 110 (N = 93 from Cohort A, and N = 17
from Cohort B). There were therefore 88 patients with samples from both time points in
Cohort A.
The patient demographic and injury-related details are shown in Table 1, and are compared
between the two cohorts. Patients in Cohort B had worse physiological parameters for haemo-
dynamic shock and coagulopathy when compared to Cohort A, with lower median SBP (90 vs
114; p = 0.0002) and HR (105 vs 87; p = 0.0004), as well as higher INR and PTT ratio (both
p = 0.020). Otherwise their demographic and injury patterns were not significantly different
between cohorts.
Table 1. Patient characteristics according to patient cohort.
Characteristic All
(N = 122)
Cohort A
(N = 105)
Cohort B
(N = 17)
p-value
Age, mean (SD) 41 (19) 41 (20) 40 (18) 0.816
Male, N (%) 108 (87) 90 (86) 16 (94) 0.466
BMI, median (IQR) 25 (23–28) 25 (23–28) 25 (22–29) 0.891
Smoker, N (%) 55 (45) 47 (45) 8 (47) >0.999
Alcohol intoxication, N (%) 19 (16) 19 (18) 0 (0) 0.071
Co-morbidities
N (%) 26 (21) 23 (22) 3 (18) >0.999
CCI, median (range) 0 (0–5) 0 (0–5) 0 (0–4) 0.814
ISS, median (IQR) 25 (12–34) 24 (10–36) 27 (17–34) 0.446
Injury mechanism, N (%)
Blunt 101 (81) 86 (82) 13 (76) 0.738
Penetrating 23 (19) 19 (18) 4 (24)
GCS, median (IQR) 12 (4–15) 13 (4–15) 9 (3–14) 0.232
Lactate (mmol/l), median (IQR) 3.7 (2.5–6.4) 3.5 (2.5–6.3) 6.0 (3.6–10.2) 0.071
SBP (mmHg), median (IQR) 111 (97–122) 114 (99–124) 91 (61–108) 0.0002a
HR (min-1), median (IQR) 89 (79–100) 87 (76–99) 108 (98–118) 0.0004a
INR, median (IQR) 1.1 (1.0–1.2) 1.1 (1.0–1.2) 1.2 (1.1–1.2) 0.020a
PTT ratio, median (IQR) 0.9 (0.8–1.0) 0.9 (0.8–0.9) 0.9 (0.9–1.1) 0.020a
Outcomes
Hospital-free days, median (IQR) 6 (0–20) 8 (0–20) 0 (0–5) 0.097
ICU-free days, median (IQR) 20 (8–29) 22 (10–29) 8 (0–18) 0.003a
Mortality, n (%) 19 (16) 16 (15) 3 (18) 0.728
PE, n (%) 1 (0.8) 1 (1.0) 0 (0) >0.999
All continuous data are presented as either mean or median, with standard deviation or interquartile range in parentheses respectively, as indicated (with
the exception that Charlson Comorbidity Index is shown with range in parentheses); categorical data are presented as N, with percentage in parentheses.
aStatistically significant according to Mann-Whitney test
BMI: body mass index; CCI: Charlson Comorbidity Index; ISS: injury severity score; GCS: Glasgow Coma Scale; SBP: systolic blood pressure; HR: heart
rate; INR: international normalised ratio; PTT: partial thromboplastin time; ICU: Intensive Care Unit; PE: pulmonary embolism
https://doi.org/10.1371/journal.pone.0189870.t001
Endotheliopathy and cell-free DNA in trauma
PLOS ONE | https://doi.org/10.1371/journal.pone.0189870 December 19, 2017 6 / 18
Cohort B had a significantly lower number of ICU-free days than those in Cohort A (8 vs
22; p = 0.003), but there were no significant differences in other outcomes between groups.
When patients who received blood product transfusion were compared to those with no
transfusion, they had a higher median lactate (6.2 mmol/l vs 3.2 mmol/l; p<0.0001), lower
median SBP (93 mmHg vs 116 mmHg; p<0.0001), and higher median HR (97 min-1 vs 87
min-1; p = 0.018) (Table 2). Although the transfused group had a higher median ISS than the
non-transfused group, this did not reach statistical significance.
Association between endothelial biomarkers and cfDNA
When samples were analysed at each specific time point (N = 100 for pre-hospital, and
N = 110 for 1–16h time points), there were significant correlations between cfDNA and both
syndecan-1 and thrombomodulin at both time points (Fig 2). When Cohorts A and B were
individually analysed, there were similarly significant correlations between cfDNA concentra-
tion and concentrations of syndecan-1 and thrombomodulin (all p<0.05). Using multivariable
linear regression, the relationships between cfDNA and both syndecan-1 and thrombomodu-
lin were independent of gender, age, GCS, lactate, SBP, and HR. However, there was an addi-
tional significant relationship between ISS and cfDNA. The modelled relationship between
cfDNA and syndecan-1 at increasing ISS values can be visualised in Fig 3.
Blood transfusion and surgery
When patients were divided into those who had surgery in between time points and those that
did not, there were 43/122 (35%) patients who had surgery. There were no significant differ-
ences in cfDNA, syndecan-1, or thrombomodulin levels at either baseline or at the second
time point between those who had surgery between time points and those who did not
(Table 3).
When patients were divided into those who had blood transfusion in between time points
and those who did not, there were 31/122 (25%) who were transfused. There were no signifi-
cant differences in cfDNA, syndecan-1, or thrombomodulin levels between groups at baseline
(Table 4). After blood product transfusion in ED, there were no differences in cfDNA or
Table 2. Patient characteristics according to requirement for transfusion.
Characteristic All
(N = 122)
Received transfusion
(N = 31)
No transfusion
(N = 91)
p-value
Age, mean (SD) 41 (19) 43 (21) 41 (19) 0.503
Male, n (%) 108 (87) 27 (87) 79 (87) >0.999
ISS, median (IQR) 25 (12–34) 27 (16–43) 23 (10–30) 0.061
Injury mechanism, n (%)
Blunt 101 (81) 23 (74) 76 (84) 0.290
Penetrating 23 (19) 8 (26) 15 (16)
GCS, median (IQR) 12 (4–15) 10 (3–14) 13 (4–15) 0.133
Lactate (mmol/l), median (IQR) 3.7 (2.5–6.4) 6.2 (4.0–9.5) 3.3 (2.3–5.1) <0.0001a
SBP (mmHg), median (IQR) 111 (97–122) 93 (69–109) 116 (103–124) <0.0001a
HR (min-1), median (IQR) 89 (79–100) 97 (81–115) 87 (76–99) 0.018a
All continuous data are presented as mean or median, with standard deviation or interquartile range in parentheses respectively; categorical data are
presented as N, with percentage in parentheses.
aStatistically significant according to Mann-Whitney test
ISS: injury severity score; GCS: Glasgow Coma Scale; SBP: systolic blood pressure; HR: heart rate
https://doi.org/10.1371/journal.pone.0189870.t002
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thrombomodulin between the transfused and non-transfused groups, but there was a signifi-
cantly higher concentration of syndecan-1 amongst the transfused group (107 ng/ml vs 43 ng/
ml; p = 0.0005) (Table 4).
Biomarkers and coagulopathy
Table 5 shows the correlations between the three biomarkers (cfDNA, syndecan-1, and throm-
bomodulin) at both time points, and both admission INR and PTT ratios. Syndecan-1 levels
were significantly correlated with INR and PTT ratios at both the pre-hospital (p = 0.036 and
p = 0.002 respectively) and in-hospital (p = 0.010 and p<0.0001 respectively) time points.
cfDNA levels were only significantly correlated with INR at the prehospital time point (with a
Fig 2. Association between (a) syndecan-1 and (b) thrombomodulin and cell-free DNA (cfDNA) according to
time points. P-values are indicated according to Spearman’s rank correlation coefficient. For both concentrations of (a)
syndecan-1 and (b) thrombomodulin, there is a significant correlation with concentration of cfDNA at both time points.
https://doi.org/10.1371/journal.pone.0189870.g002
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borderline significant p-value of 0.048), and with PTT ratio at the in-hospital time point
(p = 0.028). Thrombomodulin was only significantly correlated with PTT ratio at the in-hospi-
tal time point (p = 0.001).
Fig 3. Relationship between cell-free DNA and syndecan-1 at (a) first (prehospital) time point and (b) second (in-hospital) time point,
according to category of increasing injury severity. Solid lines represent the mean predicted values (based on the fitted model), and the shaded
areas represent the range of values covered by the 95% confidence intervals associated with those predicted values.
https://doi.org/10.1371/journal.pone.0189870.g003
Table 3. Biomarker concentrations at both time points compared between patients that had surgery between time points and those who did not.
Biomarker Had surgery
(N = 43)
No surgery
(N = 79)
p-value
Prehospital biomarkers, ng/ml
cfDNA 558 (384–956) 817 (422–2442) 0.132
Syndecan-1 49 (35–118) 59 (33–136) 0.700
Thrombomodulin 4.3 (3.4–6.2) 4.7 (3.7–6.3) 0.508
1-16h biomarkers, ng/ml
cfDNA 411 (233–1141) 457 (368–609) 0.231
Syndecan-1 65 (37–197) 46 (26–111) 0.110
Thrombomodulin 4.0 (3.5–5.4) 3.7 (3.0–4.6) 0.087
All summary data are presented as median, with interquartile range in parentheses.
cfDNA: cell-free DNA
https://doi.org/10.1371/journal.pone.0189870.t003
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Biomarker levels over time
For patients in Cohort A with cfDNA results for both time points (n = 88), the differences in
cfDNA concentrations between time points were compared to differences in concentrations of
biomarkers of endotheliopathy. When a model was fitted to examine the value of cfDNA at the
second time point as a function of the change in syndecan-1 and thrombomodulin levels,
increases in the change in syndecan-1 and thrombomodulin between time points were associ-
ated with statistically significant increases in cfDNA levels, even accounting for the cfDNA
value at the first time point. With all other covariates held at fixed values, a 50 ng/ml change in
syndecan-1 between time points corresponded to a 15% increase in cfDNA levels (95% CI
7–23%; p = 0.0002) (Fig 4A), and a 1 ng/ml change in thrombomodulin between time points
corresponded to a 20% increase in cfDNA levels (95% CI 12–29%; p<0.0001) (Fig 4B).
Biomarker levels and outcomes
When cfDNA levels were compared between those who died within 30 days and those who
survived, those who died had significantly higher levels at both the prehospital (1170 (IQR
Table 4. Biomarker concentrations at both time points compared between patients that received a blood transfusion and those who did not.
Biomarker Received transfusion
(N = 31)
No transfusion
(N = 91)
p-value
Prehospital biomarkers, ng/ml
cfDNA 828 (379–3174) 645 (410–1839) 0.501
Syndecan-1 109 (35–281) 50 (34–118) 0.095
Thrombomodulin 5.7 (3.5–7.1) 4.4 (3.6–5.9) 0.248
1-16h biomarkers, ng/ml
cfDNA 466 (299–1790) 433 (346–570) 0.191
Syndecan-1 107 (43–256) 43 (25–89) 0.0005a
Thrombomodulin 4.1 (3.5–5.2) 3.7 (2.9–4.7) 0.073
All summary data are presented as median, with interquartile range in parentheses.
asignificant according to Mann-Whitney test
cfDNA: cell-free DNA
https://doi.org/10.1371/journal.pone.0189870.t004
Table 5. Correlations between biomarker concentrations at both pre-hospital (<1h) and in-hospital (1-16h) time points and admission INR and PTT
ratios.
Biomarker Correlation with biomarkers, r (95% CI)
INR p-value PTT ratio p-value
Prehospital biomarkers
cfDNA 0.195 (0.00–0.380) 0.048a 0.000 (-0.218–0.220) 0.993
Syndecan-1 0.208 (0.01–0.392) 0.036a 0.338 (0.125–0.521) 0.002a
Thrombomodulin 0.119 (-0.084–0.311) 0.119 0.195 (-0.029–0.399) 0.078
1-16h biomarkers
cfDNA 0.054 (-0.157–0.259) 0.607 0.222 (0.018–0.407) 0.028a
Syndecan-1 0.243 (0.053–0.415) 0.010a 0.428 (0.244–0.582) <0.0001a
Thrombomodulin 0.085 (-0.109–0.272) 0.377 0.328 (0.132–0.500) 0.001a
All summary data are presented as r, with 95% confidence intervals in parentheses.
aSignificant according to Spearman’s rank correlation coefficient
INR: international normalised ratio; PTT: partial thromboplastin time; cfDNA: cell-free DNA
https://doi.org/10.1371/journal.pone.0189870.t005
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Fig 4. Relationship between cfDNA levels at the second time point and change in (a) syndecan-1 and (b)
thrombomodulin concentrations between time points. Solid lines represent the mean predicted values
(based on the fitted model), and the shaded areas represent the range of values covered by the 95% confidence
intervals associated with those predicted values.
https://doi.org/10.1371/journal.pone.0189870.g004
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538–5279) ng/ml vs 617 (IQR 391–1731) ng/ml; borderline p-value of 0.049) and in-hospital
(636 (IQR 410–1569) ng/ml vs 432 (IQR 322–577) ng/ml; p = 0.030) time points (Fig 5A).
There were no significant differences between groups in terms of survival for the prehospital
or in-hospital levels of syndecan-1 (Fig 5B) or thrombomodulin (Fig 5C).
When hospital-free days and ICU-free days were compared to both prehospital and in-hos-
pital biomarkers, there were significant negative correlations between cfDNA and syndecan-1
levels and these outcomes, but thrombomodulin levels did not have any significant correla-
tions (Table 6). Only one patient had a thromboembolic event (Table 1), therefore no compari-
sons could be made with biomarker levels.
Fig 5. Comparison at both time points according to 30-day mortality for levels of (a) cell-free DNA; (b) syndecan-1; and (c) thrombomodulin.
*p<0.05 according to Mann-Whitney U test.
https://doi.org/10.1371/journal.pone.0189870.g005
Table 6. Correlations between biomarker concentrations at both pre-hospital (<1h) and in-hospital (1-16h) time points and length of stay
outcomes.
Biomarker Correlation with outcomes, r (95% CI)
Hospital-free days p-value ICU-free days p-value
Prehospital biomarkers
cfDNA -0.390 (-0.546 –-0.207) <0.0001a -0.385 (-0.542 –-0.201) <0.0001a
Syndecan-1 -0.217 (-0.399 –-0.017) 0.029a -0.187 (-0.373–0.014) 0.060
Thrombomodulin -0.140 (-0.331–0.062) 0.161 -0.130 (-0.321–0.072) 0.194
1-16h biomarkers
cfDNA -0.331 (-0.490 –-0.150) 0.0003a -0.334 (-0.493 –-0.154) 0.0003a
Syndecan-1 -0.224 (-0.399 –-0.034) 0.018a -0.207 (-0.384 –-0.016) 0.029a
Thrombomodulin -0.165 (-0.346–0.028) 0.083 -0.178 (-0.357–0.015) 0.062
All summary data are presented as r, with 95% confidence intervals in parentheses.
aSignificant according to Spearman’s rank correlation coefficient
ICU: intensive care unit; cfDNA: cell-free DNA
https://doi.org/10.1371/journal.pone.0189870.t006
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Discussion
The main finding from the current study is that there is a strong association between circulat-
ing levels of cfDNA and biomarkers of endotheliopathy following trauma, independent of
physiological parameters. Neither transfusion nor surgery were associated with higher levels of
cfDNA. There were strong associations between levels of cfDNA and clinical outcomes. These
associations were observed in both pre-hospital (<1h) and in-hospital (1-16h) environments,
and changes in endothelial biomarkers had the same directional change as those of cfDNA
between these time points. These findings suggest that the presence of cfDNA within the circu-
lation and endotheliopathy of trauma may be mechanistically linked, confirming findings of
previous preclinical [10, 23, 28, 29] and clinical [15, 24, 25] studies. To our knowledge, our
study is the first to report this association within the pre-hospital period of evacuation follow-
ing injury, supporting the hypothesis that this is an early phenomenon, occurring within min-
utes, rather than hours, of injury. The half-life of cfDNA has been reported as under 2 hours
[30], which implies that persistently elevated levels of cfDNA over subsequent days may be due
to sustained production or reduced clearance by DNAse. Since the half-lives are similarly
short for syndecan-1 [31, 32] and thrombomodulin [33], our findings that the rise or fall in
cfDNA is associated with similar patterns in endothelial biomarker levels suggest that they
may share a common pathway.
An observational clinical study of this kind cannot demonstrate a causal link between
endotheliopathy and increase in release of cfDNA, or whether an increase in cfDNA from
injured tissues causes endotheliopathy, making preclinical data the best source for hypotheses.
There is evidence that NETs cause damage to endothelial cells due to the degradation of VE-
cadherin and activation of β-catenin signalling [29]. When NETs are free in the circulation,
they may promote tissue injury and oedema [34], and can bind to endothelial cells and cause
direct injury [28]. After prolonged exposure to NETs, endothelial cells are more likely to die
than non-exposed cells or those only exposed for a short period of time [35]. We propose that
the most likely sequence of events is that cfDNA from cellular injury, surgical intervention,
and the production of NETs by circulating activated immune cells injures the vascular endo-
thelium, which in turn releases new cfDNA.
There has been recent evidence that in addition to endogenous sources of cfDNA, injured
patients may be exposed to further fragments of mtDNA from transfused packed red blood
cells, plasma, and platelets, and that delivery of these to patients may increase the risk of trans-
fusion-related lung injury and acute respiratory distress syndrome [36, 37]. In the current
study, blood transfusion was not associated with higher levels of cfDNA, even when the trans-
fusion group had worse parameters for perfusion (lactate) and haemodynamic compromise
(SBP and HR). The significantly higher syndecan-1 levels in the transfused group may repre-
sent a greater amount of glycocalyx shedding amongst the patients with haemorrhagic shock, a
finding in keeping with other studies of the endothelium following trauma[38]. Although we
were not able to confirm the previous findings that transfusion may increase the amount of
cfDNA, these were a heterogeneous group of patients, and non-randomised. It is unknown
whether differences may have occurred after our study time points (i.e. >16 hours).
Biomarkers such as cfDNA, syndecan-1, and thrombomodulin have not yet entered clinical
utility, and their roles within diagnosis and management of trauma are still uncertain. Since
the current study has shown that raised levels of these biomarkers are associated with poorer
clinical outcomes such as mortality and length of stay in hospital or ICU, they may therefore
have some prognostic value. Their potential role in diagnosis and treatment is not yet known.
Best practice guidelines recommend the use of goal-directed therapy aimed at correcting coa-
gulopathy using viscoelastic assays such as rotational thromboelastometry or
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thromboelastography [39]. Since cfDNA, thrombomodulin, and syndecan-1 have all been
shown to be associated with coagulopathy[8, 9, 14, 15, 17, 18], a finding that was confirmed in
the current study, they represent possible sources of further information (in addition to visco-
elastic assays) to the trauma clinician during resuscitation. A previous investigation reported
better patient outcomes when there was a decrease in cfDNA between time points [40]. In our
study, a decrease in cfDNA was associated with a similar decrease in both syndecan-1 and
thrombomodulin. The reduction in these biomarkers suggests a relative restoration of the
endothelium and reduction in cell injury and NET production, which may partly explain any
better clinical outcomes previously observed.
The current study combines analysis of blood samples from two different cohorts of trauma
patients; Cohort A included patients who had any form of injury as long as it was likely to have
an ISS>8, whereas Cohort B included patients with severe injuries and the additional burden
of haemorrhagic shock. Despite the differences in these cohorts, there was an equally compel-
ling relationship between cfDNA and endotheliopathy within each cohort as well as within the
whole group. Furthermore, the association between syndecan-1, thrombomodulin, and
cfDNA remained consistent independently of physiological and transfusion status. It is tempt-
ing to conclude that these biomarkers represent a common pathway. However, it is possible
that other confounding variables are responsible for the elevation and decrease in both cfDNA
and endothelial biomarkers. For example, levels of mtDNA have been linked to surgical
trauma, injury severity and volume of intravenous fluids delivered [41, 42]. The current study
shows a relationship between ISS and cfDNA. The precise relationship between cfDNA and
the endothelium, although examined in detail in preclinical studies, requires further analysis
in humans. In particular, attention should be given to causality between these biomarkers, so
that a full narrative of trauma from initial injury to endotheliopathy, coagulopathy, and organ
dysfunction might be better understood.
Limitations
The current study reports a relatively high burden of injury (median ISS of 25) amongst
patients, and therefore the findings may not necessarily be translatable to less severely injured
patients. However, the range in ISS and injury mechanisms within the study cohorts may
increase the reliability and translatability of the main findings. The number of patients is rela-
tively low, and from a single Major Trauma Centre in a developed trauma network. Our find-
ings may benefit from corroboration in further sites and other trauma systems. In particular,
our trauma network does not currently deliver pre-hospital blood products, and it is unknown
what effects these may have on cfDNA and endothelial biomarkers before arrival in hospital.
Although we report markers of endotheliopathy, the clinical impact (such as the potential
for soft tissue oedema and alterations to normal fluid balance) was not examined in the current
study. Thromboelastography was not available during this study. Instead, INR was used as a
marker of acute traumatic coagulopathy as previously described[43]. Further clinical investiga-
tions of the impact of endotheliopathy on vascular permeability and thromboelastography are
warranted.
Conclusions
We report an association between concentrations of cfDNA and markers of endotheliopathy
(syndecan-1 and thrombomodulin) within the circulation following injury that is independent
of physiological parameters. This relationship is present within the first hour of injury, persists
over time, with an increase or decrease in concentration of one biomarker being reflected by a
similar change in the others. There is an association between cfDNA and injury severity, and
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higher levels of cfDNA are associated with longer lengths of stay and mortality. Although cau-
sality cannot be established, these findings are in keeping with previous evidence that there is a
close mechanistic relationship between circulating DNA, vascular endothelial injury, and
poorer clinical outcomes.
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